SCHEMBL6173330

SCHEMBL6173330

CC(c1ccncc1CO)C1NC(=O)N(c2ccc(S(=O)(=O)C(F)(F)F)cc2)C1=O

nearest known ligand 0.40

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 2/20 0.40
NAMPT P43490 1/20 0.33
LMNA P02545 2/20 0.33
TRPV3 Q8NET8 2/20 0.32
MAPK1 P28482 1/20 0.31
HTT P42858 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
NR1H2 P55055 1/20 0.31
NR1H3 Q13133 1/20 0.31
CTSS P25774 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6175260 0.93 IGF1R (0.39) IGF1RNAMPTLMNAMAPK1HTT
SCHEMBL6175529 0.89 IGF1R (0.37) IGF1RLMNA
SCHEMBL6175175 0.88 IGF1R (0.36) IGF1RLMNAMAPK1HTTSMN1; SMN2
SCHEMBL6171408 0.86 IGF1R (0.35) IGF1RLMNAMAPK1HTTSMN1; SMN2
SCHEMBL6175297 0.84 LMNA (0.39) IGF1RLMNATRPV3MAPK1HTT
SCHEMBL6174640 0.84 IGF1R (0.37) IGF1RLMNATRPV3MAPK1HTT
SCHEMBL6173547 0.84 IGF1R (0.39) IGF1RLMNA
SCHEMBL6172336 0.84 CACNA1B (0.34) IGF1RLMNATRPV3CTSS
SCHEMBL6170251 0.84 IGF1R (0.33) IGF1RNAMPTLMNA
SCHEMBL6176021 0.83 IGF1R (0.34) IGF1RLMNAMAPK1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1599464-A2 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS Aventis Pharma S.A. (FR) 2005-11-30 EP disclosed
WO-2004070050-A2 CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2004-08-19 WO disclosed